General Information of Drug (ID: DMI4RUI)

Drug Name
PF-07038124
Synonyms
PF-07038124; M6ZU548FWD; PF07038124; UNII-M6ZU548FWD; 2415085-44-6; Pyridine, 3-((4R)-2-hydroxy-1,2-oxaborolan-4-yl)-5-(4-methoxy-3-propoxyphenyl)-; GTPL11950; US11559538, Example 4; BDBM589740; GLXC-25702; Example 4 [US2020108083A1]; PF 07038124 [WHO-DD]; HY-144683; CS-0433935; (R)-4-(5-(4-Methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol; 3-[(4R)-2-hydroxyoxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)pyridine
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Phase 2 [1]
Psoriasis EA90 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL is unavailable 2D MOL
Chemical Identifiers
Formula
C18H22BNO4
Canonical SMILES
B1(CC(CO1)C2=CN=CC(=C2)C3=CC(=C(C=C3)OC)OCCC)O
InChI
InChI=1S/C18H22BNO4/c1-3-6-23-18-8-13(4-5-17(18)22-2)14-7-15(11-20-10-14)16-9-19(21)24-12-16/h4-5,7-8,10-11,16,21H,3,6,9,12H2,1-2H3/t16-/m0/s1
InChIKey
KXVKOYCGACSUPP-INIZCTEOSA-N
Cross-matching ID
PubChem CID
148293990
TTD ID
D81WBS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05375955) A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Pfzer